Expected U.S. launch in 2023.
First and currently only biological targeting P-selectin.
MCL is an aggressive form of NHL
Shown to reduce regular RBC transfusions in adults with beta thalassemia.
Fourth filgrastim biosimilar from Sandoz, expected ASAP.
Could lead to falsely high or low results, especially troponin assays.
Approved for ages 65 and older.
First and currently only rifabutin-based H. pylori therapy approved.
Delayed-release oral capsules for various forms of the disease.
Commercial launch suspended due to manufacturer liquidity.